APM
ALBO

Avidity Partners Management’s Albireo Pharma Inc ALBO Stock Holding History

Avidity Partners Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-125,000
Closed -$4.69M – 129
2020
Q4 		$4.69M Buy
+125,000
New +$4.55M 0.15% 82

Other funds holding ALBO

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Avidity Partners Management's ALBO Position: Q1 2021 in Review

Avidity Partners Management sold out of Albireo Pharma Inc (ALBO) in Q1 2021, closing a stake of 125,000 shares — an estimated $4.69M sold.

Avidity Partners Management first reported a position in ALBO in Q4 2020 and held it in 1 quarter. The position peaked at $4.69M in Q4 2020. 100 funds tracked by Wall St. Rank hold ALBO as of Q1 2021.

  • Avidity Partners Management reported no remaining Albireo Pharma Inc position as of Q1 2021 after selling out during the quarter.
  • Avidity Partners Management sold 125,000 Albireo Pharma Inc shares in Q1 2021, an estimated $4.69M.
  • Avidity Partners Management first reported a position in Albireo Pharma Inc in Q4 2020 and held it in 1 quarter.
  • Avidity Partners Management's Albireo Pharma Inc position peaked at $4.69M in Q4 2020.
  • 100 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2021.

Based on Avidity Partners Management's 13F filing for Q1 2021, filed 17 May 2021.